Sana Biotechnology, Inc.
NASDAQ:SANA
4.29 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 30.865 | 27.731 | 17.914 | 10.171 | 3.921 | 0.001 |
| Gross Profit
| -30.865 | -27.731 | -17.914 | -10.171 | -3.921 | -0.001 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 221.641 | 201.003 | 306.499 | 257.879 | 119.375 | 4.014 |
| General & Administrative Expenses
| 73.299 | 71.561 | 50.41 | 28.27 | 21.777 | 8.412 |
| Selling & Marketing Expenses
| 73.226 | 0 | 0 | 0 | 0 | -4.206 |
| SG&A
| 73.299 | 71.561 | 50.41 | 28.27 | 21.777 | 4.206 |
| Other Expenses
| 0 | -0.674 | 0.305 | 0.097 | -0.029 | 0 |
| Operating Expenses
| 294.94 | 272.564 | 356.909 | 286.149 | 141.152 | 8.22 |
| Operating Income
| -325.805 | -272.564 | -356.909 | -286.149 | -141.152 | -8.221 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 42.55 | 3.088 | 0.981 | 0.844 | 2.827 | -5.026 |
| Income Before Tax
| -283.255 | -269.476 | -355.928 | -285.305 | -138.325 | -13.247 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -3.088 | -11.746 | -6.668 | -7.547 | 0 |
| Net Income
| -283.255 | -266.388 | -344.182 | -278.637 | -130.778 | -13.247 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.46 | -1.41 | -2.07 | -1.49 | -0.7 | -0.071 |
| EPS Diluted
| -1.46 | -1.41 | -2.07 | -1.49 | -0.7 | -0.071 |
| EBITDA
| -294.94 | -272.564 | -356.909 | -286.149 | -139.326 | -8.22 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |